Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2006-9-18
pubmed:abstractText
Third molar extraction is a common procedure frequently accompanied by moderate or severe pain, and involves sufficient numbers of patients to make studies relatively easy to perform. The aim of the present study was to determine the efficacy and safety of the therapeutic combination of 10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine citrate, and 2.5 mg cyanocobalamin (Rheumazin) when compared with 20 mg piroxicam alone (Feldene) in mandibular third molar surgery. Eighty patients scheduled for removal of the third molar were included in this randomized and double-blind study. They received (vo) Rheumazin or Feldene 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated with a measuring tape and adverse effects and patient satisfaction were recorded. There was no statistically significant difference in facial swelling between Rheumazin and Feldene (control group). Both drugs were equally effective in the control of pain, with Rheumazin displaying less adverse effects than Feldene. Therefore, Rheumazin appears to provide a better risk/benefit ratio in the mandibular molar surgery. Since the side effects resulting from nonsteroidal anti-inflammatory drug administration are a severe limitation to the routine use of these drugs in clinical practice, our results suggest that Rheumazin can be a good choice for third molar removal treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0100-879X
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1241-7
pubmed:meshHeading
pubmed-meshheading:16981050-Adolescent, pubmed-meshheading:16981050-Adult, pubmed-meshheading:16981050-Anti-Inflammatory Agents, pubmed-meshheading:16981050-Dexamethasone, pubmed-meshheading:16981050-Double-Blind Method, pubmed-meshheading:16981050-Drug Therapy, Combination, pubmed-meshheading:16981050-Edema, pubmed-meshheading:16981050-Female, pubmed-meshheading:16981050-Humans, pubmed-meshheading:16981050-Male, pubmed-meshheading:16981050-Middle Aged, pubmed-meshheading:16981050-Molar, Third, pubmed-meshheading:16981050-Muscle Relaxants, Central, pubmed-meshheading:16981050-Orphenadrine, pubmed-meshheading:16981050-Pain, Postoperative, pubmed-meshheading:16981050-Pain Measurement, pubmed-meshheading:16981050-Piroxicam, pubmed-meshheading:16981050-Prospective Studies, pubmed-meshheading:16981050-Severity of Illness Index, pubmed-meshheading:16981050-Tooth Extraction, pubmed-meshheading:16981050-Vitamin B 12, pubmed-meshheading:16981050-Vitamin B Complex
pubmed:year
2006
pubmed:articleTitle
Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery.
pubmed:affiliation
Unidade de Farmacologia Clínica, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't